Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 80,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $70.14, for a total value of $5,611,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Agios Pharmaceuticals, Inc. (AGIO) traded up 0.81% on Thursday, hitting $70.82. 320,924 shares of the stock were exchanged. Agios Pharmaceuticals, Inc. has a 1-year low of $39.24 and a 1-year high of $71.40. The company’s market capitalization is $3.43 billion. The company has a 50-day moving average price of $63.02 and a 200 day moving average price of $55.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The firm had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The business’s revenue was up 62.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.47) EPS. Analysts anticipate that Agios Pharmaceuticals, Inc. will post ($7.08) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/05/insider-selling-agios-pharmaceuticals-inc-agio-ceo-sells-80000-shares-of-stock.html.

A number of research firms have weighed in on AGIO. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Royal Bank Of Canada began coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective on the stock. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. Finally, ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $75.20.

Several hedge funds and other institutional investors have recently bought and sold shares of AGIO. Bank of Montreal Can boosted its position in shares of Agios Pharmaceuticals by 11.7% during the 1st quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 216 shares in the last quarter. Blue Sky Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth approximately $129,000. QS Investors LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $144,000. Russell Investments Group Ltd. boosted its position in shares of Agios Pharmaceuticals by 163.9% during the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 1,583 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 3,123 shares in the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.